Abstract:Highlights • PM is a novel HDACI/IIb inhibitor with better selectivity and inhibitory activity than currently marketed HDAC inhibitors. • PMF completely overcomes the problem of PM's poor solubility, and improved PM stability and pharmacokinetic properties. • PMF effectively inhibits disease progression and abrogates leukemia stem cells survival in TKI-resistant CML mouse model. • Simultaneous targeting of I/IIb HDACs and glutaminolysis could sufficiently eradicated LSCs in the mouse model. Purinostat Mesylate (PM) is a novel highly selective and active HDAC I/IIb inhibitor, and the injectable formulation of PM (PMF) based on the compound prescription containing cyclodextrin completely can overcome PM's poor solubility and improves its stability and pharmacokinetic properties. Here, we showed that PM effectively repressed the survival of Ph + leukemia cells and CD34 + leukemia cells from CML patients in vitro . In vivo studies demonstrated that PMF significantly prevented BCR-ABL(T315I) induced CML progression by restraining leukemia stem cells (LSCs), which are insensitive to chemotherapy and responsible for CML relapse. Mechanism studies revealed that targeting HDAC I/IIb repressed several important factors for LSCs survival including c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR, as well as interrupted some critical biologic processes. Additionally, PMF increased glutamate metabolism in LSCs by increasing GLS1. The combination of PMF and glutaminase inhibitor BPTES synergistically eradicated LSCs by altering multiple key proteins and signaling pathways which are critical for LSC survival and self-renewal. Overall, our findings represent a new therapeutic strategy for eliminating LSCs by targeting HDAC I/IIb and glutaminolysis, which potentially provides a guidance for PMF clinical trials in the future for TKI resistance CML patients. Graphical abstract The presence of leukemia stem cells and TKI treatment resistance are the root causes why CML disease cannot be cured. PM, the novel highly selective HDAC I/IIb inhibitor. We prepared the free PM into the injectable formulation of PM (PMF) based on the compound prescription containing cyclodextrin, which can improve the solubility, stability, and pharmacokinetic properties of free PM, and reduces toxicity. Using BCR-ABL(T315I) induced TKI resistance CML mouse model, we demonstrated that PMF could significantly prevent CML disease and diminish survival and maintenance of LSCs. However, PMF treatment alone also increased glutaminolysis of LSCs by increasing GLS1 expression. Treatment of PMF combination with targeting GLS1 can synergistically impede disease and eradicate LSCs of CML. Our findings provide a guidance for PMF clinical trials in the future for TKI resistance CML patients. Download : Download high-res image (276KB) Download : Download full-size image

Kill Two Birds with One Stone: A Multifunctional Dual‐Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome‐Positive Leukemia

Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects

The Novel Anticancer Agent JNJ-26854165 is Active in Chronic Myeloid Leukemic Cells with Unmutated BCR/ABL and T315I Mutant BCR/ABL Through Promoting Proteosomal Degradation of BCR/ABL Proteins

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)

Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery

Abstract 3915: PBA2, a dual BCR-ABL and GSK3βkinases inhibitor, represses a wide array of Imatinib resistant cell lines in chronic myeloid leukemia

Synergy Between Proteasome Inhibitors And Imatinib Mesylate In Chronic Myeloid Leukemia

Abstract 398: Overriding Drug Resistance in Philadelphia Chromosome-Positive Acute B Lymphoblastic Leukemia by Targeting Both BCR-ABL and MAP4K Signaling Pathways

Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells

Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.

BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?

HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells

Chk1 Inhibitors Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia

Synergic Effects of Proteasome Inhibitor Ps-341 and Tyrosine Kinase Inhibitor Sti571 on Chronic Myeloid Leukemia Cells and Bcr-Abl Oncoprotein in Vitro and in Vivo.

Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia

Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia

Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy

Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies

Discovery and Characterization of a Novel Highly Potent and Selective Type II Native and Drug-Resistant V299L Mutant BCR-ABL Inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

A Tetrameric Protein Scaffold As a Nano-Carrier of Antitumor Peptides for Cancer Therapy.